Alto Neuroscience

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP net loss of $27.6M compared to the $25.5M expected. GAAP EPS of -$0.65 beat the mean consensus of -$0.73, primarily due to a higher-than-anticipated share count rather than operational outperformance. A significant increase in R&D spending to $22.1M reflects the acceleration of the ALTO-207 PACE program, while a successful $100M financing in July extended the cash runway through 2030, mitigating near-term liquidity concerns.